Cognate BioServices

Cognate BioServices is a prominent contract development and manufacturing organization (CDMO) that specializes in cell and cell-mediated gene therapy products. The company leverages extensive experience in regenerative medicine and blood-derived products to serve a diverse range of clients, including pharmaceutical companies, biotech firms, and research institutions. Operating in the highly specialized market of cell and gene therapy, Cognate BioServices provides end-to-end solutions encompassing manufacturing, supply chain management, storage, shipping, and clinical trial logistics.

Cognate BioServices operates a compliant cGMP facility in Baltimore, MD, with 80,000 square feet of space, fully qualified by the U.S. FDA and EU Annex I standards. The company has successfully manufactured and delivered products across the US, EU, and Asia, ensuring the highest quality and traceability through all stages of the supply chain. Ancillary services include support, logistics, and other critical functions that maintain product consistency and quality from development to commercialization.

The business model is centered around providing comprehensive CDMO services, enabling clients to transition seamlessly from clinical development to commercial production. Revenue is generated through long-term contracts and partnerships with clients, offering a range of services tailored to meet specific needs.

Keywords: CDMO, cell therapy, gene therapy, regenerative medicine, cGMP, supply chain, logistics, clinical trials, biotech, pharmaceutical.